

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

Newsletter Issue 1: April, 2018



# SHARP

Severe Heterogenous Asthma  
Research collaboration  
Patient-centered

## Progress on integrating severe asthma registries - SHARP

Dear SHARP collaborators,

We would like to thank you for your interest and participation in the SHARP (Severe Heterogenous Asthma Research collaboration, Patient-centered) Clinical Research Collaboration (CRC). We are very pleased to share with you the first issue of the SHARP Newsletter to introduce you to the progress of the Fast Mover project as well as the first SHARP Stakeholder board meeting, which will be held during the ERS spring meeting on Wednesday 25 April, 2018 in Zurich.

### Fast Mover project

The Fast Mover project is a central element for the concept validation of SHARP and was launched in November 2017. Nine different registries across Europe (Belgium, Germany, Hungary, Italy, Poland, Spain, Sweden, The Netherlands, and the United Kingdom) have started to gather the data of their respective registry databases to address the following research questions:

- What are the baseline clinical characteristics recorded in registries of individuals with severe asthma?
- What are the treatment regimens prior to the start of add-on therapies for severe asthma therapies (biologics, thermoplasty, high altitude therapy) or 6 months after stopping?

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

## Stakeholder board meeting

The aim of the Stakeholder board meeting in Zurich is to kick off a strong and worthy partnership between the different stakeholders and agree on the ethos of SHARP. We, the SHARP chairs, will update you in Zurich on how the SHARP project has advanced in the first year and will share with you the plans for the coming year. Most importantly, we will work together towards a consensus of research priorities to set up the first common research agenda for SHARP.

Preparations for the Zurich meeting are well underway. Two teleconferences have been organised with each of the following stakeholder groups:

- National leads and Steering Committee members
- Industry partners
- Scientific panel
- Patient Advisory Group

During the first teleconference, potential research questions/opportunities of interest were discussed and ways of clustering similar projects into programmes were explored to enable prioritisation. The objective of the second teleconference for each stakeholder group is to narrow down each group's selection to the top three research priorities for presentation during the Zurich meeting.


After the presentations of the top three questions from each stakeholder group, breakout sessions with mixed groups of multiple stakeholders will allow further discussion, to review and cluster research priorities and then present the new top three research questions to all attendants of the meeting.

This first stakeholder board meeting is of high importance as it will set the project direction for the next two-three years. We are delighted to have received to date confirmation from around 40 participants, including seven members of the Patient Advisory Group. We would like all participants to join the discussions with an open, enthusiastic and cooperative mind to maximise the chances of reaching a good consensus on the first set of research priorities.

If you have any question or suggestions, please contact the [ERS office](#) who will relay your question to us.

We very much look forward to meeting you in Zurich!

With kind regards





<b>Subscribe</b>	<b>Past Issues</b>	<a href="#">Elisabeth Bel</a>	<a href="#">Dominique Hamerlijnck</a>	<a href="#">Toni Latimer-Simpson</a>	<b>Translate</b> ▼
<a href="#">Co-Chair</a>	<a href="#">Co-Chair</a>	<a href="#">Patient, Co-Chair</a>	<a href="#">Patient, Deputy Chair</a>		

---

*Copyright © 2018 European Respiratory Society, All rights reserved.*

[unsubscribe from this list](#) [update subscription preferences](#)

 [SHARP webpage - coming soon!](#)       [Contact us](#)

---